PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

PURPOSE OF REVIEW: The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS: Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atheroscler...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Curr Opin Lipidol
Autori principali: Chapman, M. John, Stock, Jane K., Ginsberg, Henry N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2015
Soggetti:
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927326/
https://ncbi.nlm.nih.gov/pubmed/26780005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000239
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi